EpiCast Report: Macular Edema – Epidemiology Forecast to 2026

Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). The risk for ME is also higher in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

GlobalData’s epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across these markets.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed retinopathy population will grow by 31.29% over the forecast period, at an Annual Growth Rate (AGR) of 3.13%, from 980,030 cases in 2016 to 1,286,637 cases by 2026. The total prevalent cases of ME following BRVO in the 7MM increased from 307,341 total prevalent cases in 2016 to 347,397 total prevalent cases in 2026. The total prevalent cases of ME following CRVO in the 7MM increased from 125,326 total prevalent cases in 2016 to 149,226 total prevalent cases in 2026, at an AGR of 1.91% during the forecast period.

Scope

The Macular edema (ME) EpiCast Report and EpiCast Model an overview of the risk factors, comorbidities, and the global and historical trends for ME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population, diagnosed prevalent cases of clinically significant DME among the diagnosed DME population, and the total prevalent cases of ME following BRVO and CRVO segmented by sex and age (ages 20 years and older) in these markets.

The ME epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The ME EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global ME market.

Quantify patient populations in the global ME market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ME therapeutics in each of the markets covered.

Understand magnitude of ME population by age and sex.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Prevalent Cases of T2D

3.4.4 Diagnosed Prevalent Cases of T1D

3.4.5 Diagnosed Prevalent Cases of Diabetic Retinopathy

3.4.6 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

3.4.7 Diagnosed Prevalent Cases of Clinically significant DME Among the Diagnosed DME Population

3.4.8 Total Prevalent Cases of BRVO and CRVO

3.4.9 Total Prevalent Cases of ME following BRVO and CRVO

3.5 Epidemiological Forecast for Macular Edema (2016–2026)

3.5.1 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

3.5.2 Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

3.5.3 Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

3.5.4 Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed the DME Population

3.5.5 Total Prevalent Cases of ME following BRVO

3.5.6 Age-Specific Total Prevalent Cases of ME Following BRVO

3.5.7 Sex-Specific Total Prevalent Cases of ME Following BRVO

3.5.8 Total Prevalent Cases of ME following CRVO

3.5.9 Age-Specific Total Prevalent Cases of ME Following CRVO

3.5.10 Sex-Specific Total Prevalent Cases of ME Following CRVO

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for DME

Table 2: 7MM, Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population, 2016

Table 3: 7MM, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, Ages ≥20 Years, N, Selected Years 2016–2026.

Table 4: 7MM, Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed DME Population, Both Sexes, Ages ≥20 Years, N, Selected Years 2016–2026

Table 5: 7MM, Total Prevalent Cases of ME following BRVO, Both Sexes, Ages ≥20 Years, N, Selected Years 2016–2026

Table 6: 7MM, Total Prevalent Cases of ME following CRVO, Both Sexes, Ages ≥20 Years, N, Selected Years 2016–2026

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, Ages ≥20 Years, N, 2016 and 2026

Figure 2: 7MM, Total Prevalent Cases of ME Following BRVO, Both Sexes, Ages ≥20 Years, N, 2016 and 2026

Figure 3: 7MM, Total Prevalent Cases of ME Following CRVO, Both Sexes, Ages ≥20 Years, N, 2016 and 2026

Figure 4: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D Among the General Population

Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of T1D Among the General Population

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Diabetic Retinopathy Among the Diagnosed Diabetes Population

Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population

Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of Clinically-Significant DME Among the Diagnosed Diabetic Retinopathy Population

Figure 9: 7MM, Sources Used , Total Prevalent Cases of BRVO and CRVO Among the General Population

Figure 10: 7MM, Sources Used, Total Prevalent Cases of ME following BRVO

Figure 11: 7MM, Sources Used, Total Prevalent Cases of ME following CRVO

Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, N, 2016

Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, N, 2016

Figure 14: 7MM, Age-Specific Total Prevalent Cases of ME Following BRVO, Both Sexes, N, 2016

Figure 15: 7MM, Sex-Specific Total Prevalent Cases of ME following BRVO, Ages ≥20 Years, N, 2016

Figure 16: 7MM, Age-Specific Total Prevalent Cases of ME Following CRVO, Both Sexes, N, 2016

Figure 17: 7MM, Sex-Specific Total Prevalent Cases of ME following CRVO, Ages ≥20 Years, N, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports